Big pharma — Maximum earnings, minimum responsibilities

Richa Chintan

People’s Dispatch | August 24, 2021

Photo: Wikimedia Commons

The contrast between the devastating effects of the COVID-19 pandemic on the lives and livelihood of the working-class population and the soaring profits of big pharma companies in the corresponding period is abhorrent.

Despite the huge jump in revenues during the global crisis and a forecast for the continuation of the good run—owing to an assured market for vaccines, drugs and diagnostics in the years to come—big pharma is reportedly lobbying against the proposed global deal on tax overhaul. Last month, about 130 countries agreed to the US call for a global minimum rate of corporate tax of 15%.

Read More »

Trump Unveils Plan That Would See Big Pharma Reap Massive Profits from COVID-19 Vaccine

by Raul Diego

MintPress News | May 15, 2020

coronavirus vaccine Feature photo

A former Big Pharma executive and a four-star General have just been appointed by President Trump to lead a “Manhattan project-style effort to develop a vaccine for the novel coronavirus.” The effort, called Operation Warp Speed, has set a goal to create 300 million doses of a non-existent vaccine by January.Read More »

How One of Big Pharma’s Most Corrupt Companies Plans to Corner the COVID-19 Cure Market

by Whitney Webb and Raul Diego

MintPressNews | April 14, 2020

Emergent COVID-19 Feature photo

WASHINGTON DC (The Last American Vagabond) — In August 2001, biopharmaceutical company BioPort faced imminent disaster. A series of company scandals, controversial federal bail-outs and severe, adverse health reactions among U.S. troops were causing both Congress and the Pentagon to reconsider its multi-million dollar contract to provide the military with an anthrax vaccine.

Formed for the sole purpose of acquiring a publicly-owned company in Michigan that held the exclusive license to manufacture the only FDA-approved anthrax vaccine in the United States, BioPort sought to quickly expand the size and scope of its contracts with the U.S. military. This strategy was made possible thanks to the former head of the Joints Chiefs of Staff, Adm. William Crowe, who would prove highly instrumental in the rise of BioPort’s vaccine monopoly and its subsequent, aggressive hiring of former government officials as lobbyists.Read More »

HeberFERON, a unique Cuban medicine

One-of-a-kind medicine to treat skin cancer, developed and produced by Cuba’s Center for Genetic Engineering and Biotechnology, is now available nation-wide

Granma | April 09, 2020

HeberFERON, a unique Cuban drug to treat skin cancer. Photo: CIGB
The extension of therapeutic coverage to all municipalities across the country, with the opening of more sites, is the key strategy in the application program for HeberFERON; a one-of-a-kind medicine to treat skin cancer (basal cell carcinoma), developed and produced by Cuba’s Center for Genetic Engineering and Biotechnology (CIGB).Read More »

Sellling Side Effects: Big Pharma’s Marketing Machine

by Michelle Llamas

Greanville Post | July 26, 2019

ABOVE: Jardiance DTC ad, considered by many as one of the most annoying. Like most commercials, Big Pharma ads are intrusive and mendacious, and they make people look stupid, but with their constant reminders about our health vulnerabilities, they also depress our quality of life. Who needs 24/7 reminders about a multitude of diseases lying in wait to ambush us?

“[T]his advertising promotes only the most expensive products, it drives prescription costs up and also encourages the ‘medicalization’ of American life — the sense that pills are needed for most everyday problems that people notice, and many that they don’t.” —Jerry Avorn, New York Times

Read More »

We’ve got a pain problem

John’s Hopkins University | June 17, 2017

So, this happened.

Ohio wants its money back — all $175 million. The state is suing five big pharma companies to get it, saying the companies committed fraud by flooding the market with addictive opioid painkillers, and in part, causing a state and nationwide drug epidemic.

The state claims the drug companies ran a marketing scheme that persuaded doctors to give opioids to uninformed patients and “illegally promoted the widespread use of opioids for chronic pain,” while falsely denying the powerful drugs’ risks. Ohio spent $175 million between 2006 and 2016 on the pills themselves through Medicaid and other health care programs, and millions more on addiction, health and foster care services.Read More »

Report: Pharmaceutical Industry Funding Influences Lawmakers in Contentious Medicare Part B Reform Battle

PUBLIC CITIZEN | 11 July, 2016

WASHINGTON – Members of the U.S. House of Representatives who sided with the pharmaceutical industry in an ongoing lobbying fight over Medicare reforms received 82 percent more in campaign contributions for the 2016 election cycle than members who did not side with the industry, according to a new Public Citizen report.

The report, “Pharma’s Orders,” sheds light on the role of money in politics in the ongoing debate surrounding the Centers for Medicare & Medicaid Services’ (CMS) proposed Medicare Part B demonstration project. The project is intended to reduce costs to taxpayers and patients by decreasing doctors’ incentive to administer the most expensive products provided under Medicare Part B.Read More »

Targeting Big Pharma Price Gouging, Sanders Backs California Ballot Fight

by Jon Queally, staff writer

Commn Dreams | 10 May, 2016

“The political establishment is getting nervous,” Sanders told more than 16,000 people at a soccer stadium in Sacramento, California on Monday night. (Photo:

Backing a citizen-led initiative to combat soaring drugs prices in California, Democratic presidential candidate Bernie Sanders on Tuesday endorsed a ballot proposal designed to curb what he described as a corporate “rip-off” of the state’s sick and vulnerable.

Read More »